EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment
- 1 November 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 2 (2), 1-6
- https://doi.org/10.1200/po.17.00277
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Patient monitoring through liquid biopsies using circulating tumor DNAInternational Journal of Cancer, 2017
- Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical OncologyJournal of Oncology Practice, 2017
- Integrating liquid biopsies into the management of cancerNature Reviews Clinical Oncology, 2017
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupAnnals of Oncology, 2016
- Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trialsAnnals of Oncology, 2014
- KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatmentsPersonalized Medicine, 2013
- Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins.Molecular and Cellular Biology, 1988